India, July 27 -- argenx SE (ARGX,ARGX.BR), a Dutch immunology innovation company, announced Monday its agreement to acquire Forte Biosciences, Inc. (FBRX) for $77 per share in cash, representing a total equity value of around $2.2 billion. With the acquisition, argenx would add Forte Biosciences' First-in-Class anti-CD122 Antibody, FB102, to its immunology pipeline.
In the overnight activity, Forte Biosciences shares were jumping around 22.05 percent, trading at $66.86.
The per share deal price represents a premium of around 86% to Forte Biosciences' volume-weighted average price since reporting positive Phase 1b data in vitiligo on July 9.
The boards of directors of both companies have approved the transaction, which is expected to clo...